How is relugolix administered?
Patent Information
- Application Number
- JP2023528189
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-02-19
- Filing Date
- 2021-11-10
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
Smart Images

Figure 00000000_0000_ABST
Abstract
Claims
1. A pharmaceutical composition comprising N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea or a pharma- ceutically acceptable salt thereof: administering to the subject an oral loading dose combination comprising 1 mg to 360 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, or a corresponding amount of a pharma- ceutical acceptable salt thereof, once daily for at least one day during a first treatment period; and 1. A pharmaceutical composition for treating prostate cancer, comprising: 1 mg to 120 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, or a corresponding amount of a pharma- ceutical acceptable salt thereof; and 0.01 mg to 1000 mg of a P-gp inhibitor or a combination of a P-gp inhibitor and a CYP3A inhibitor, administered to a subject once daily for at least 24 consecutive weeks during a second treatment period.
2. 2. The medicament of claim 1 , comprising: administering to a subject once daily an oral combination comprising 1 mg to less than 120 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, or a corresponding amount of a pharma- ceutical acceptable salt thereof; and 0.01 mg to 1000 mg of a P-gp inhibitor or a combination of a P-gp inhibitor and a CYP3A inhibitor; Discontinuing administration of the combined oral combination during a rest period to allow serum testosterone levels to increase; and A medicament used to resume administration of the combined oral combination once daily at the end of the rest period.
3. An oral combination comprising 1 mg to less than 360 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea or a corresponding amount of a pharma- ceutical acceptable salt thereof; and 0.01 mg to 1000 mg of a P-gp inhibitor or a combination of a P-gp inhibitor and a CYP3A inhibitor, for simultaneous or sequential use in a subject in need of treatment for prostate cancer.
4. 1. An oral combination for use in treating a subject in need of treatment for prostate cancer, comprising: administering to the subject an oral loading dose combination comprising from 1 mg to less than 360 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, or a corresponding amount of a pharma- ceutical acceptable salt thereof, once daily for at least one day during a first treatment period; and 1. An oral combination comprising: 1 mg to 120 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, or a corresponding amount of a pharma- ceutical acceptable salt thereof; and 0.01 mg to 1000 mg of a P-gp inhibitor or a combination of a P-gp inhibitor and a CYP3A inhibitor, administered to a subject once daily for at least 24 consecutive weeks during a second treatment period.
5. 1. An oral combination comprising from 1 mg to less than 120 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea or a corresponding amount of a pharma- ceutical acceptable salt thereof; and from 0.01 mg to 1000 mg of a P-gp inhibitor or a combination of a P-gp and a CYP3A inhibitor for use in treating a subject in need of such treatment, wherein the oral combination is used as follows: Administer the oral combination to the subject once daily; Withdrawal of the oral combination during the rest period to allow serum testosterone levels to increase; and At the end of the rest period, subjects resume treatment with the oral combination once daily.
6. 5. The method of claim 1, or the oral combination of claim 4, wherein the oral loading dose combination further comprises from 0.01 mg to 1000 mg of a P-gp inhibitor or a combination of a P-gp inhibitor and a CYP3A inhibitor.
7. said administration comprising once daily administration of 15 mg to 30 mg, 15 mg to 40 mg, or 15 mg to 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, or a corresponding amount of a pharma- ceutical acceptable salt thereof, and 0.01 mg to 1000 mg of a P-gp inhibitor or a combination of a P-gp inhibitor and a CYP3A inhibitor; Optionally, administration of the oral maintenance dose formulation begins the day after administration of the last dose of the oral loading dose formulation. A drug according to any one of claims 1, 2 or 6, or an oral combination according to any one of claims 3 to 6.
8. 8. The oral combination formulation according to claim 1, 2, 6 or 7, or the oral combination formulation according to claim 3, wherein the oral combination formulation is administered for 12 consecutive weeks or more, 24 consecutive weeks or more, 48 consecutive weeks or more, 52 consecutive weeks or more, 72 consecutive weeks or more, or 96 consecutive weeks or more.
9. The oral combination according to any one of claims 3 to 8, wherein administration is discontinued after at least 24 consecutive weeks of treatment, after at least 36 consecutive weeks of treatment, or after at least 52 consecutive weeks of treatment.
10. said administration is preceded by daily administration of a preparatory dose of only a P-gp inhibitor or a combination of a P-gp inhibitor and a CYP3A inhibitor for at least five days; 10. The pharmaceutical composition of claim 1, 2 or 6-8, or the oral combination of claim 3, 4 or 5, optionally wherein the pre-dose of the P-gp inhibitor is from 0.01 mg to 100 mg of said P-gp inhibitor.
11. A pharmaceutical composition comprising N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea or a pharma- ceutically acceptable salt thereof: A medicament for treating uterine fibroids, endometriosis, adenomyosis, heavy menstrual bleeding, or pain associated with uterine fibroids, endometriosis, or adenomyosis in premenopausal women, comprising a combination of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea or a pharma- ceutical acceptable salt thereof, estradiol or an estradiol equivalent, a progestin, and a P-gp inhibitor or a P-gp inhibitor and a CYP3A inhibitor, administered to premenopausal women.
12. The agent of claim 11 administered once daily to a premenopausal female in combination with: 1 mg to 40 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea, or a corresponding amount of a pharma- ceutically acceptable salt thereof; 0.5 mg to 2 mg estradiol or the corresponding amount of estradiol equivalent; 0.01 mg to 5 mg of a progestin; and 0.01 mg to 1000 mg of a P-gp inhibitor or a combination of a P-gp inhibitor and a CYP3A inhibitor.
13. 1. An oral combination comprising 1 mg to 40 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N'-methoxyurea or a corresponding amount of a pharma- ceutical acceptable salt thereof; 0.5 mg to 2 mg of estradiol or a corresponding amount of estradiol equivalent; 0.01 mg to 5 mg of a progestin; and 0.01 mg to 1000 mg of a P-gp inhibitor or a combination of a P-gp inhibitor and a CYP3A inhibitor, for simultaneous or sequential use in the treatment of one or more of the following: uterine fibroids, endometriosis, adenomyosis, heavy menstrual bleeding, or pain associated with uterine fibroids, endometriosis, or adenomyosis in premenopausal women.
14. 14. The agent of claim 12, or the oral combination of claim 13, wherein the premenopausal woman is a peri-menopausal woman.
15. 15. A medicament according to claim 12 or 14, or an oral combination according to claim 13 or 14, wherein the pain is pelvic pain or dysmenorrhea.
